Extendicare (TSE:EXE – Free Report) had its price objective hoisted by BMO Capital Markets from C$11.00 to C$13.50 in a report issued on Monday morning,BayStreet.CA reports.
A number of other research firms have also recently weighed in on EXE. Royal Bank of Canada lifted their price objective on shares of Extendicare from C$9.50 to C$11.00 and gave the company a “sector perform” rating in a report on Thursday, November 28th. Cormark raised shares of Extendicare to a “moderate buy” rating in a report on Wednesday, February 19th. Finally, TD Securities boosted their target price on shares of Extendicare from C$9.50 to C$10.50 and gave the stock a “hold” rating in a research note on Thursday, November 14th. Three analysts have rated the stock with a hold rating and one has issued a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and an average target price of C$11.50.
Get Our Latest Stock Analysis on Extendicare
Extendicare Price Performance
Extendicare Announces Dividend
The firm also recently announced a monthly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 17th will be paid a dividend of $0.04 per share. The ex-dividend date is Friday, February 28th. This represents a $0.48 annualized dividend and a yield of 3.81%. Extendicare’s dividend payout ratio (DPR) is presently 61.20%.
Extendicare Company Profile
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC”) homes and one of the largest private-sector providers of publicly funded home health care services.
Further Reading
- Five stocks we like better than Extendicare
- ESG Stocks, What Investors Should Know
- Bearish Investors Can Seek Refuge in Recession-Resistant ETFs
- Stock Sentiment Analysis: How it Works
- 3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- 3M to Hit $175 by Mid-Year, and Higher Highs Are Likely
Receive News & Ratings for Extendicare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Extendicare and related companies with MarketBeat.com's FREE daily email newsletter.